Cardiotoxicity in Breast Cancer: Challenges of Multimodal Therapies
Cardiotoxicity in breast cancer has emerged as a significant concern due to the increasing use of multimodal therapies, which combine different treatment modalities such as chemotherapy, targeted therapies, and radiation. While these therapies have improved survival rates, they can also have detrimental effects on the heart, leading to cardiotoxicity.
For the second edition of this series of weekly educational broadcasts, brought to you by IC-OS's partnership with Radcliffe, Dr Paul Cottu (Institut Curie, FR), Dr Mariana Mirabel (Institut Mutualiste Montsouris, FR) and Dr Francesco Cribari (Institut Mutualiste Montsouris, FR) discuss the challenges that multimodal therapies present for heart damage when used to treat breast cancer.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS are collectively improving the overall outcomes including survival and quality of life. IC-OS aim to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
This is an independent activity run by the International Cardio-Oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. The IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
This broadcast is supported by
Prof Daniel Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.
Prof Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute and the Chief of Staff of the Abramson Cancer Center.
He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.
Dr Paul Cottu is an oncologist at Institut Curie, Paris, FR.
Dr Cottu's top areas of expertise include Breast Cancer, Ovarian Cancer, Endometrial Cancer, Mastectomy, and Endoscopy.
Over the past 15 years, his clinical research has consisted of co-authoring 159 peer reviewed articles and participating in 7 clinical trials.
Dr Mariana Mirabel is a cardiologist at Institut Mutualiste Montsouris, Paris, FR.
She is head of the first dedicated cardio-oncology department in Paris, France, at the Hôpital Européen Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Université Paris Descartes.